Trial Profile

A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Nov 2025 According to Nouscom media release, company announced the presentation of new clinical and translational data on its lead candidate NOUS-209 at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting.
30 Oct 2025 According to Nouscom media release, data from this trial will be included in an oral late-breaker as well as a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting being held in National Harbor, MD, USA on November 5-9, 2025.
20 Oct 2025 Planned End Date changed from 30 Sep 2025 to 30 Sep 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com